Imaging Biometrics has entered an agreement with imaging biomarker developer MedImageMetric to commercialize its patented quantitative susceptibility mapping (QSM) software.
MedImageMetric’s software, QSMetric, is now available for sale through Imaging Biometrics as an annual license subscription.
QSMetric is an automated software for MRI that measures how tissue responds to magnetic fields, allowing clinicians to quantify magnetic susceptibility changes in tissue, reflecting changes in iron deposition, microbleeds, demyelination, calcification, and other markers of disease progression, as well as monitor response to treatment.
According to the two firms, the collaboration also opens the door to joint development opportunities, including the development of AI-powered analytics and clinical decision support tools using QSMetric data, integration of QSMetric into Imaging Biometric’s software for neurocharacterization, and expansion into imaging workflows for neuro-oncology, neurodegeneration, and vascular disorders.
